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ABSTRACT. The high burden of infectious diseases in adults aged 60 years and older is disproportionate, considering that many of these diseases are vaccine-preventable. Based on careful analysis of the reasons for vaccination barriers/failures in the European population, the two European geriatric and gerontological societies (the European Union Geriatric Medicine Society [EUGMS] and the International Association of Gerontology and Geriatrics -European Region [IAGG-ER]) propose careful adaptation of current vaccine guidelines to promote preventive aspects, concerning both life threatening-diseases (influenza, pneumococcal pneumonia and tetanus/diphtheria) and diseases which adversely impact patients' quality of life (pertussis and herpes zoster). This consensus statement is designed to support official recommendations and im-
The main purposes of the Joint Working Group were: 1) to conduct an inventory of the current practical guidelines for universally recommended vaccines in adults in European countries, and to compare guidelines with those of the USA; 2) to propose an adaptation of current vaccine guidelines designed to support official recommendations; 3) to stress the importance of sustaining a lifecourse vaccine program from childhood to adulthood until extreme old age; 4) to support the public health, social and economic value of vaccines to prevent infectious diseases in the whole population; and 5) to enhance the willingness to vaccinate and the public acceptance of vaccination.
The group was composed of geriatricians designated by the two societies (EUGMS: SM and JPM and IAGG-ER: RM and HW) and experts in immunology and vaccines (B-GL and PHL), pneumococcal vaccine (CC) and influenza vaccine (KN) and public health (Theri Kilpi), who all worked on a voluntary basis.
Each of the working member was in charge of a specific topic (formulating the bibliography, reporting at each of the three meetings, and participating in the writ-
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ing of the paper related to their main expertise). The academic director of the EUGMS assured the coordination of the various chapters and wrote the first draft. All group members participated in its improvement and agreed with the content of the final version. The draft statement was then submitted to the executive boards of the two societies.
Vaccines should be part of a healthy aging strategy, considering that currently the period from retirement age (from 55 to 65 years in most Western European countries) to death is generally two to three decades. Several clinical considerations must be included in it (Table 1 
-Revaccinations: an annual influenza vaccination is needed, as each year's vaccine is adapted to new seasonal strains. Repeated annual influenza immunizations broaden antigenic protection, if the new strains are closely related (3). Pneumococcal vaccine is recommended every 5 years and TdaP every 10 years. Further studies are needed to determine the duration of the protective effect of a single herpes zoster vaccination and to establish whether a booster for it is required. Regular booster vaccinations throughout life are important to maintain the ability to respond to recall antigens with aging.
Other special indications for vaccinations should be considered: -In case of trauma or a new medical event, a booster (or a complete vaccination) of tetanus toxoid or TdaP may be provided if the previous tetanus vaccination was given over 10 years previously. -In case of repeated hospitalizations, pneumococcal vaccine should be considered, if the last immunization dated back 5 years. -At the time of admission to residential care (approximately 85 years in most Western European countries), a new clinical assessment of vaccine history is recommended, to ascertain if any vaccine updates are needed. This assessment needs to consider TdaP, influenza, pneumococcal and herpes zoster vaccines.
Willingness to vaccinate and public acceptance of vaccination
These vaccine guidelines for citizens aged 60 years and older, proposed by the two European geriatric and gerontological societies, would be justified if there is evidence such programs are cost-effective and safe.
Despite existing controversies concerning: a) estimated influenza-related mortality; b) the effectiveness of influenza vaccine in older adults; c) possible selection biases in cohort studies (4, 5) ; and d) the need for country-specific assessment (6) . Most recent analysis studies of influenza vaccine show a high-impact, cost-effective service for persons aged over 50 years, and even over 70 years (7) (8) (9) (10) (11) . Already in the mid-1990s, a cost-effectiveness analysis of pneumococcal vaccination for prevention of invasive pneumococcal disease in populations aged over 65 years in 10 Western European countries justified wider use of the vaccine (12) . Most cost-effectiveness analyses of pertussis vaccination in Europe were performed in Germany and based on a Markov model; the results were more sensitive in favoring routine vaccination of adults aged 20 to 64 with TdaP, if the incidence of pertussis in this age group was greater than 120 per 100,000 population (13, 14) .
More research is needed on the cost-effectiveness of all these vaccines in adults aged 60 years and older. Community and patient values for preventing herpes zoster and post-herpetic neuralgia are currently under investigation to determine the quality-adjusted life-years saved (15) (16) (17) . Improving vaccine uptake in this population requires addressing numerous barriers to adult immunization, which involve both consumers' beliefs and healthcare professionals' practices (18, 19) .
Consensus statement
The EUGMS and IAGG-ER have formed a Joint Working Group to complement existing information, propose vaccine guidelines, and develop a consensus statement that advocates immunization in adults aged 60 years and older. This consensus statement: -Demonstrates the need to strengthen and harmonize vaccine strategies at the European level; -Recognises the importance of sustaining a life-course vaccine program; -Promotes healthy aging by increasing vaccine coverage to limit the burden of vaccine-preventable infectious diseases; -Supports the public health, social and economic value of vaccination, and even -Improves willingness to vaccinate the most rapidly growing segment of the general population. Healthcare professionals have a critical role to play in the implementation of such consensus vaccine guidelines. Communication and awareness of vaccine-preventable diseases, such as an efficient reminder, recall and information system as well as improved access to vaccines, constitute the main pillars for success in establishing a vaccine program for European citizens aged 60 years and older.
